Indication · hallucinations and delusions associated with adp

hallucinations and delusions associated with adp FDA approvals, PDUFA dates and pipeline.

Updated Snapshot 20261116T222116ZBuilt

We track 1 hallucinations and delusions associated with adp drug. No FDA approvals recorded yet.

Drugs

DrugSponsorModalityDesignations
remlifanserin (ACP-204)ACAD—Fast Track

Upcoming catalysts

No events in this view.

Past catalysts and decisions

DateDrugCompanyEventIndicationStatusSource
Nov 2023Month disclosedremlifanserin (ACP-204)ACADTrial starthallucinations and delusions associated with ADPCompletedSEC Form 10-Q

All indications · Approval rates by indication

Not submitted to search engines: Needs 2 drugs and 3 sourced events; has 1 and 1.

Questions

What hallucinations and delusions associated with adp drugs have upcoming PDUFA dates?

None disclosed.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.